R&D Systems™ Recombinant Human IFN-lambda 4 Protein

Description

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

The Recombinant Human IFN-lambda 4 Protein is derived from E. coli. The Recombinant Human IFN-lambda 4 Protein has been validated for the following applications: Bioactivity.

Order Info

The product is shipped at ambient temperature.

Specifications

• Accession Number: K9M1U5
• For Use With (Application): Bioactivity
• Formulation: Lyophilized from a 0.2μm filtered solution in Citric Acid and CHAPS.
• Gene ID (Entrez): 101180976
• Molecular Weight (g/mol): 18 kDa
• Quantity: 25μg
• Source: E. coli-derived human IFN-lambda 4 protein Ala23-Leu179 with an N-terminal Met
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
• Regulatory Status: RUO
• Endotoxin Concentration: <0.10 EU per 1μg of protein by LAL method
• Gene Alias: IFNAN, IFNL4, IFNlambda 4
• Biological Activity: Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED50 for this effect is 0.2-1.2 μg/mL.
• Conjugate: Unconjugated
• Species: Human
• Recombinant: Recombinant
• Purity or Quality Grade: >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie Blue Staining.

For Research Use Only